Samsung Bioepis First to Receive Positive CHMP Opinion on a Trastuzumab Biosimilar with ONTRUZANT®
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on ONTRUZANT® , a biosimilar candidate referencing Herceptin® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170915005388/en/
The CHMP’s positive opinion will now be referred to the European Commission (EC) which will decide on the grant of a marketing authorization for ONTRUZANT® . If a marketing authorization is granted by the EC, ONTRUZANT® will be commercialized in the European Union by MSD, which is known as Merck in the United States and Canada.
“We are proud to see ONTRUZANT become the first trastuzumab biosimilar
recommended for approval in Europe, where breast cancer remains the most
common form of cancer affecting women. If approved, we hope ONTRUZANT
will play an important role expanding patient access to trastuzumab
across the region,” said Christopher Hansung Ko, President & CEO of
Samsung Bioepis. “Through relentless process innovation and an
uncompromising commitment to quality, we remain dedicated to advancing
one of the industry's strongest biosimilar pipelines, so that more
cancer patients and healthcare systems across Europe will benefit from
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
i Herceptin ® is a registered trademark of Genentech Inc.
Samsung Bioepis Co., Ltd.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SM-OPTICS23.2.2018 15:02 | pressemeddelelse
SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes
TX-HASHGAINS23.2.2018 14:58 | pressemeddelelse
Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response
CARDINALITY23.2.2018 14:09 | pressemeddelelse
Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”
IBC23.2.2018 12:05 | pressemeddelelse
IBC2018 Welcomes Channel 4’s Keith Underwood as Guest Chair of Content Steering Group
SES-S.A.23.2.2018 08:02 | pressemeddelelse
SES S.A.: Full Year and Fourth Quarter 2017 Results
LION/GEM-LUXEMBOURG-323.2.2018 08:02 | pressemeddelelse
Lion/Gem Luxembourg 3 S.a.r.l. Announce First Quarter Results for FY 2018
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum